Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AI

NASDAQ · AIDX

20/20 Biolabs, Inc. Common Stock

Healthcare · Medical - Devices

$0.48

Up+$0.01 (+1.05%)

Updated Sep 17, 2026, 7:39 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
18.77M
P/E ratio
-8.94
Dividend yield
0.00%
52-week range
$0.40 – $3.08
Volume
34.25K
Avg. volume
551.63K

Price performance

AIDX price history

1M range · 20 trading sessions · Daily adjusted prices

AIDX closed at $0.48 after 20 trading sessions, down 5.47% for the selected period.

Last close
$0.48
Period change
-5.47%
Period low
$0.48
Period high
$0.63
Daily close
View OHLC price history
AIDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.4785$0.50$0.4601$0.480834.25K
Sep 15, 2026$0.5205$0.5315$0.4682$0.475833.58K
Sep 14, 2026$0.531$0.6084$0.514$0.520550.18K
Sep 11, 2026$0.56$0.5979$0.5301$0.5644.78K
Sep 10, 2026$0.579$0.6091$0.5341$0.540442.97K
Sep 9, 2026$0.5991$0.5991$0.5645$0.564626.52K
Sep 8, 2026$0.60$0.60$0.568$0.577918.46K
Sep 4, 2026$0.5931$0.6212$0.582$0.5915131.45K
Sep 3, 2026$0.607$0.615$0.5991$0.611595.24K
Sep 2, 2026$0.65$0.68$0.61$0.6304122.5K
Sep 1, 2026$0.616$0.6249$0.60$0.615635.98K
Aug 31, 2026$0.65$0.65$0.614$0.616238.36K
Aug 28, 2026$0.615$0.67$0.615$0.624121.86K
Aug 27, 2026$0.5829$0.63$0.5738$0.6197120.69K
Aug 26, 2026$0.5204$0.5799$0.5204$0.56369.37K
Aug 25, 2026$0.5791$0.5813$0.5182$0.528245.82K
Aug 24, 2026$0.56$0.56$0.5101$0.5182132.58K
Aug 21, 2026$0.5241$0.6436$0.5045$0.5543230.86K
Aug 20, 2026$0.5272$0.54$0.5045$0.514120.8K
Aug 19, 2026$0.5113$0.556$0.5078$0.508643.02K

Latest AIDX news

The latest Smart Investors Daily articles mentioning AIDX.

Stock researchCompany · Overview

AIDX research

Overview

Company profile and research snapshot.

Company profile

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AIDX recent ratings
DateFirmRatingTarget
May 11, 2026Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results

Price targets for Healwell AI have been adjusted within a CA$1.50 to CA$2.00 range, with some analysts moving up to CA$2.00 and others trimming down to CA$1.50. This split reflects different views on how recent quarterly execution lines up with what investors should be willing to pay for the stock today. As you read on, you will see how to interpret these shifting targets and track the evolving narrative around Healwell AI for your own decision making. Analyst Price Targets don't always...

Yahoo · Aug 28, 2026

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 28, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laborat

Yahoo · Aug 26, 2026

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, labora

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By